Type 2 Diabetes: key endpoint results by drug
The key endpoints of Type 2 Diabetes trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Type 2 Diabetes page.
HbA1c, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Afrezza | -0.7% | -0.8% (Metformin & Secretagogues) | — | wk 12 · n 169 | NCT00332488 Phase 3, primary |
| Albenatide | -0.8% | -0.5% | −0.4 | 1.5 mg · wk 12.14 · n 44 | NCT00638716 Phase 2, primary |
| Alogliptin | -0.7% | -0.1% | −0.6 | 25 mg QD · wk 26 · n 126 | NCT00286429 Phase 3, primary |
| Anagliptin | -0.5%a | 0.2% | −0.7 | anagliptin 200 mg · wk 24 | NCT01529528 Phase 3, primary |
| Berberine ursodeoxycholate (HTD1801) | -0.6% | 0.1% | −0.7 | 1000 mg bid · wk 18 · n 26 | NCT03656744 Phase 2, secondary |
| Bexagliflozin | -0.8% | -0.4% | −0.5 | 20 mg · wk 24 · n 1046 | NCT02558296 Phase 3, primary |
| bimagrumab | -0.8% | 0.3% | −1.1 | 10 mg/kg · wk 24 · n 36 | NCT03005288 Phase 2, secondary |
| Canagliflozin | -0.4% | 0.4% | −0.8 | 100/300 mg · wk 26 · n 84 | NCT03170518 Phase 3, primary |
| Chiglitazar | -1.1%a | -0.5% | −0.6 | 48mg · wk 24 | NCT04807348 Phase 3, primary |
| Cofrogliptin | -1.0%a | -1.1% (linagliptin 5 mg) | — | cofrogliptin (HSK7653) 25 mg · wk 24 | NCT04564872 Phase 3, primary |
| Dapagliflozin | -0.9% | -0.2% | −0.7 | 10 mg AM · wk 24 · n 65 | NCT00528372 Phase 3, primary |
| Dapagliflozin/linagliptin (Dapalina) | -0.8%a | 0.1% | −0.9 | wk 24 | NCT06329674 Phase 3, primary |
| dulaglutide | -1.3% | -0.5% | −0.8 | 1.5 mg · wk 24 · n 132 | NCT02597049 Phase 3, primary |
| efpeglenatide | -1.6% | -0.5% | −1.1 | 6 mg · wk 30 · n 103 | NCT03353350 Phase 3, primary |
| efsubaglutide alfa | -1.8%a | -0.7% | −1.1 | Efsubaglutide 3 mg · wk 24 | NCT04998032 Phase 2/3, primary |
| Empagliflozin | -0.7% | -0.2% | −0.5 | 10mg · wk 24 · n 217 | NCT01159600 Phase 3, primary |
| Enavogliflozin | -0.8%a | -0.8% (dapagliflozin) | — | wk 24 | NCT04634500 Phase 3, primary |
| Ertugliflozin | -1.0% | 0.2% | −1.2 | 15 mg · wk 26 · n 151 | NCT01958671 Phase 3, primary |
| Evogliptin | -0.2%a | 0.1% | −0.3 | evogliptin 5mg · wk 24 | NCT02946541 Phase 3, primary |
| Gemigliptin | -0.8%a | 0.4% | −1.2 | wk 12 | NCT01968044 Phase 3, primary |
| glimepiride | -1.1% | -0.6% (Insulin Glargine) | — | 1.5 mg · wk 52 · n 263 | NCT01075282 Phase 3, primary |
| HDG1901 | -2.0%a | -2.0% (reference Ozempic) | — | wk 32 | NCT06739044 Phase 3, primary |
| IcoSema | -1.6% | -0.9% (Insulin Icodec) | — | wk 52 · n 598 | NCT05352815 Phase 3, primary |
| insulin degludec | -1.4% | -1.6% (Insulin Icodec) | — | wk 26 · n 294 | NCT04795531 Phase 3, primary |
| insulin detemir | -0.5% | 0.0% (Lira 1.8) | — | wk 26 · n 160 | NCT00856986 Phase 3, primary |
| Insulin Efsitora Alfa | -0.8% | -0.7% (Insulin Degludec) | — | 500 U/mL · wk 26 · n 649 | NCT05275400 Phase 3, primary |
| insulin glargine | -0.6% | -0.8% (Insulin Icodec) | — | wk 26 · n 201 | NCT06340854 Phase 3, primary |
| Insulin glargine (Basaglar) | -1.3% | -1.3% (Lantus) | — | wk 24 · n 369 | NCT01421459 Phase 3, primary |
| insulin glulisine | -0.5% | -0.5% (Insulin Lispro) | — | n 115 | NCT01194258 Phase 2, primary |
| insulin icodec | -0.8% | -0.6% (Insulin Glargine) | — | wk 26 · n 204 | NCT06340854 Phase 3, primary |
| Insulin Lispro | -1.2% | -1.1% (Insulin Glargine) | — | 1.5 mg · wk 26 · n 138 | NCT01621178 Phase 3, primary |
| Insulin lispro (Lyumjev) | -0.4% | -0.4% (Insulin Lispro (Humalog)) | — | wk 26 · n 334 | NCT03214380 Phase 3, primary |
| Insulin sudelidec (INS068) | -1.3%a | -1.4% (insulin glargine) | — | wk 26 | NCT05699408 Phase 3, primary |
| JW0201 | -0.8%a | -0.0% | −0.8 | wk 24 | NCT05814393 Phase 3, primary |
| Lanifibranor | -0.7% | -0.1% | −0.6 | wk 24 · n 20 | NCT03459079 Phase 2, secondary |
| Linagliptin | -0.6% | 0.1% | −0.6 | 5 mg · wk 24 · n 618 | NCT00954447 Phase 3, primary |
| Liraglutide (Victoza) | -0.6% | 0.4% | −1.1 | 1.8 mg · wk 26 · n 66 | NCT01541215 Phase 3, primary |
| lixisenatide | -0.6% | 0.1% | −0.6 | wk 24 · n 172 | NCT01798706 Phase 3, primary |
| mazdutide | -2.1%a | -0.1% | −2 | mazdutide 6mg · wk 24 | NCT05628311 Phase 3, primary |
| metformin | 0.2% | 0.1% | +0.1 | wk 12 · n 46 | NCT02099838 Phase 4, primary |
| Mitiglinide | -0.6% | 0.1% | −0.7 | wk 16 · n 118 | NCT02154347 Phase 4, primary |
| Omarigliptin | -0.3% | -0.5% | +0.1 | 25 mg · wk 24 · n 102 | NCT01814748 Phase 3, primary |
| orforglipron | -1.4% | -0.1% | −1.3 | 36 mg · wk 40 · n 141 | NCT05971940 Phase 3, primary |
| ORMD-0801 | -0.6% | -0.1% | −0.5 | Once Daily (QHS) · wk 12 · n 59 | NCT03467932 Phase 2, primary |
| Prusogliptin | -0.6%a | -0.0% | −0.6 | wk 24 | NCT04161430 Phase 3, primary |
| retatrutide | -2.0% | -0.1% | −2 | 12 mg (2 mg) · wk 24 · n 43 | NCT04867785 Phase 2, primary |
| SAR341402 | -0.4% | -0.3% (NovoLog/NovoRapid) | — | wk 26 · n 301 | NCT03211858 Phase 3, primary |
| Saxagliptin | -0.7% | -0.3% | −0.4 | 5 mg · wk 24 · n 300 | NCT00757588 Phase 3, primary |
| Semaglutide (Ozempic) | -1.6% | 0% | −1.6 | 1.0 mg weekly · wk 30 · n 130 | NCT02054897 Phase 3, primary |
| Sitagliptin | -0.6% | 0.2% | −0.8 | 100 mg · wk 24 · n 229 | NCT00087516 Phase 3, primary |
| Sotagliflozin (Inpefa) | -0.8% | -0.3% | −0.5 | 400 mg · wk 26 · n 259 | NCT02926950 Phase 3, primary |
| survodutide | -1.7% | -0.2% | −1.4 | 2.7 mg · wk 16 · n 33 | NCT04153929 Phase 2, primary |
| Teneligliptin | -0.7% | -0.0% | −0.7 | 20 mg · wk 24 · n 122 | NCT02924064 Phase 3, primary |
| Tirzepatide (Mounjaro) | -2.1% | 0.0% | −2.1 | 15 mg · wk 40 · n 116 | NCT03954834 Phase 3, primary |
| Trelagliptin | -0.7% | 0.0% | −0.7 | 25 mg · wk 12 · n 55 | NCT02512068 Phase 3, primary |
| Vildagliptin | 7.2% | 7.4% (SU+Metformin) | — | wk 24 · n 19 | NCT01871558 Phase 3, secondary |
| Visepegenatide (PB-119) | -1.4%a | -0.6% | −0.7 | wk 24 | NCT04504370 Phase 3, primary |
Drugs checked with no result here: 19 not posted, 18 trial running, 17 not reported.
Body weight, change (kg)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Albenatide | -2.0 | -1.6 | −0.4 | 1.5 mg · wk 12.14 · n 44 | NCT00638716 Phase 2, secondary |
| Alogliptin | 0.6 | 0.6 | ±0 | 25 mg QD · wk 26 · n 124 | NCT00286429 Phase 3, secondary |
| Bexagliflozin | -3.0 | -0.4 | −2.6 | 20 mg · wk 48 · n 922 | NCT02558296 Phase 3, secondary |
| bimagrumab | -4.0 | -0.6 | −3.4 | 10 mg/kg · wk 24 · n 36 | NCT03005288 Phase 2, secondary |
| Canagliflozin | -2.9 | -0.8 | −2.1 | 300 mg daily · wk 12 · n 62 | NCT00642278 Phase 2, secondary |
| Dapagliflozin | -3.2 | -2.2 | −1 | 10 mg AM · wk 24 · n 69 | NCT00528372 Phase 3, secondary |
| dulaglutide | -0.8 | 0.4 | −1.2 | 1.5 mg · wk 28 · n 133 | NCT04591626 Phase 3, secondary |
| efpeglenatide | -3.2 | -1.4 | −1.8 | 6 mg · wk 30 · n 103 | NCT03353350 Phase 3, secondary |
| Empagliflozin | -2.1 | -0.4 | −1.7 | 10mg · wk 24 · n 217 | NCT01159600 Phase 3, secondary |
| Ertugliflozin | -2.3 | -0.4 | −1.9 | 15 mg · wk 18 · n 2746 | NCT01986881 Phase 3, secondary |
| glimepiride | -2.4 | 0.1 (Glim) | — | 1.8 mg · wk 16 · n 224 | NCT00614120 Phase 3, secondary |
| IcoSema | -3.7 | 2.0 (Insulin Icodec) | — | wk 52 · n 606 | NCT05352815 Phase 3, secondary |
| insulin degludec | 2.3 | 2.8 (Insulin Icodec) | — | wk 26 · n 294 | NCT04795531 Phase 3, secondary |
| insulin detemir | -0.2 | -0.9 (Lira 1.8) | — | wk 26 · n 162 | NCT00856986 Phase 3, secondary |
| Insulin Efsitora Alfa | 3.2 | 2.7 (Insulin Degludec) | — | wk 26 · n 465 | NCT05362058 Phase 3, secondary |
| insulin glargine | 0.6 | 2.0 (Insulin Icodec) | — | wk 26 · n 202 | NCT06340854 Phase 3, secondary |
| Insulin glargine (Basaglar) | 1.9 | 2.2 (Lantus) | — | wk 24 · n 370 | NCT01421459 Phase 3, secondary |
| insulin glulisine | 0.5 | 0.2 (Insulin Glargine+Metformin+Glimepiride) | — | wk 24 · n 48 | NCT00360698 Phase 4, secondary |
| insulin icodec | 2.0 | 0.6 (Insulin Glargine) | — | wk 26 · n 204 | NCT06340854 Phase 3, secondary |
| Insulin Lispro | -2.8 | 1.1 (Insulin Glargine) | — | 1.5 mg · wk 26 · n 140 | NCT01621178 Phase 3, secondary |
| Linagliptin | 1.4 | -0.0 | +1.5 | 5 mg · wk 26 · n 49 | NCT03429543 Phase 3, secondary |
| Liraglutide (Victoza) | -2.5 | -0.9 | −1.6 | 1.8 mg · wk 26 · n 60 | NCT01541215 Phase 3, secondary |
| lixisenatide | -0.6 | 1.0 (Insulin Glulisine) | — | wk 26 · n 295 | NCT01768559 Phase 3, primary |
| metformin | -0.4 | -1.1 (Met) | — | 5 mg once daily + metformin once daily · wk 14 · n 287 | NCT01438814 Phase 4, secondary |
| Omarigliptin | -0.4 | 1.5 (Glimepiride) | — | wk 54 · n 375 | NCT01682759 Phase 3, secondary |
| orforglipron | -7.3 | -1.3 | −6 | 36 mg · wk 40 · n 141 | NCT05971940 Phase 3, secondary |
| retatrutide | -12.8 | -1.9 | −11 | 12 mg (2 mg) · wk 24 · n 43 | NCT04867785 Phase 2, secondary |
| Saxagliptin | -1.9 | -0.4 | −1.5 | wk 24 · n 158 | NCT01646320 Phase 3, secondary |
| Semaglutide (Ozempic) | -4.9 | -0.6 | −4.3 | 1.0 mg · wk 104 · n 822 | NCT01720446 Phase 3, secondary |
| Sitagliptin | -0.5 | -1.4 (Oral Semaglutide) | — | 100 mg · wk 26 · n 335 | NCT04017832 Phase 3, secondary |
| Sotagliflozin (Inpefa) | -2.6 | -0.7 | −1.9 | 400 mg · wk 26 · n 259 | NCT02926950 Phase 3, secondary |
| survodutide | -6.9 | -1.3 | −5.6 | 2.7 mg · wk 16 · n 33 | NCT04153929 Phase 2, secondary |
| Tirzepatide (Mounjaro) | -9.5 | -0.7 | −8.8 | 15 mg · wk 40 · n 116 | NCT03954834 Phase 3, secondary |
| Vildagliptin | -0.3 | 1.4 (SU+Metformin) | — | wk 24 · n 21 | NCT01871558 Phase 3, secondary |
Drugs checked with no result here: 38 not posted, 19 trial running, 20 not reported.
HbA1c below 7%
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Alogliptin | 63.3% | 30% | +33.3 | wk 16 · n 90 | NCT01289119 Phase 3, secondary |
| Canagliflozin | 42.8% | 43% (Metformin XR) | — | 300 mg · wk 26 · n 215 | NCT01809327 Phase 3, secondary |
| Dapagliflozin | 50.8% | 31.6% | +19.2 | 10 mg AM · wk 24 · n 65 | NCT00528372 Phase 3, secondary |
| dulaglutide | 75.9% | 33.8% | +42.1 | 1.5 mg · wk 28 · n 133 | NCT04591626 Phase 3, secondary |
| Empagliflozin | 34.6% | 24.5% | +10.1 | 10 mg, 25 mg · wk 26 · n 52 | NCT03429543 Phase 3, secondary |
| Ertugliflozin | 28.2% | 15.5% | +12.7 | 15 mg · wk 18 · n 2520 | NCT01986881 Phase 3, secondary |
| glimepiride | 62.8% | 72.3% (Liraglutide) | — | wk 26 · n 269 | NCT01296412 Phase 3, secondary |
| insulin degludec | 75.3% | 35.6% (Liraglutide or Exenatide) | — | wk 26 · n 292 | NCT01676116 Phase 3, secondary |
| insulin glargine | 48.4% | 45.9% (Liraglutide) | — | wk 24 · n 467 | NCT01117350 Phase 4, primary |
| Insulin glargine (Basaglar) | 43.7% | 44.9% (Lantus®) | — | wk 24 · n 334 | NCT03338010 Phase 3, secondary |
| insulin glulisine | 22.4% | 8.8% (Insulin Glargine+Metformin+Glimepiride) | — | wk 24 · n 49 | NCT00360698 Phase 4, primary |
| Insulin Lispro | 37.5% | 34.6% (Insulin Glargine) | — | 1.5 mg · wk 26 · n 152 | NCT01621178 Phase 3, secondary |
| Linagliptin | 26.9% | 24.5% | +2.4 | 5 mg · wk 26 · n 52 | NCT03429543 Phase 3, secondary |
| Liraglutide (Victoza) | 63.7% | 36.5% | +27.2 | 1.8 mg · wk 26 · n 66 | NCT01541215 Phase 3, secondary |
| lixisenatide | 53% | 38.8% | +14.2 | wk 24 · n 185 | NCT01169779 Phase 3, secondary |
| metformin | 48.4% | 45.9% (Liraglutide) | — | wk 24 · n 467 | NCT01117350 Phase 4, primary |
| Omarigliptin | 33.5% | 34% | −0.5 | 25 mg · wk 24 · n 102 | NCT01814748 Phase 3, secondary |
| orforglipron | 79.0% | 37.1% | +41.9 | 36 mg · wk 40 · n 119 | NCT05971940 Phase 3, secondary |
| retatrutide | 86% | 18% | +68 | 12 mg (2 mg) · wk 24 · n 43 | NCT04867785 Phase 2, secondary |
| rexlemestrocel-L | 33%a | 0% | +33 | — | NCT01576328 Phase 1/2, primary |
| SAR341402 | 16.6% | 14.5% (NovoLog/NovoRapid) | — | wk 26 · n 301 | NCT03211858 Phase 3, secondary |
| Saxagliptin | 44.4% | 16.6% | +27.8 | 10 mg · wk 24 · n 180 | NCT00121667 Phase 3, secondary |
| Semaglutide (Ozempic) | 72.3% | 24.8% | +47.5 | 1.0 mg weekly · wk 30 · n 130 | NCT02054897 Phase 3, secondary |
| Sitagliptin | 49.5% | 36.8% | +12.7 | wk 20 · n 95 | NCT01485614 Phase 3, secondary |
| Sotagliflozin (Inpefa) | 29.7% | 15.8% | +13.9 | 400 mg · wk 26 · n 259 | NCT02926950 Phase 3, secondary |
| Tirzepatide (Mounjaro) | 87.9% | 19.6% | +68.3 | 15 mg · wk 40 · n 116 | NCT03954834 Phase 3, secondary |
Drugs checked with no result here: 44 not posted, 20 trial running, 21 not reported.
Fasting plasma glucose, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Albenatide | -0.8 | -0.6 | −0.2 | 1.5 mg · wk 12.14 · n 42 | NCT00638716 Phase 2, secondary |
| Alogliptin | -0.7 | 0.3 | −1 | 25 mg QD · wk 26 · n 128 | NCT00286429 Phase 3, secondary |
| Bexagliflozin | -2.5 | -1.2 | −1.3 | 20 mg · wk 24 · n 142 | NCT03259789 Phase 3, secondary |
| Canagliflozin | -0.6 | 0.2 | −0.7 | 300 mg · wk 338 · n 1377 | NCT01032629 Phase 3, secondary |
| Dapagliflozin | -1.3 | 0.2 | −1.5 | wk 24 · n 222 | NCT00984867 Phase 3, secondary |
| dulaglutide | -2.4 | -2.6 (Insulin Glargine) | — | 1.5 mg · wk 26 · n 253 | NCT01648582 Phase 3, secondary |
| efpeglenatide | 6.5 | 8.6 | −2 | 6 mg · wk 30 · n 103 | NCT03353350 Phase 3, secondary |
| Empagliflozin | -1.8 | 0.3 | −2.1 | 25 mg + 5 mg · wk 24 · n 109 | NCT01734785 Phase 3, secondary |
| Ertugliflozin | -1.9 | -0.9 | −1 | 15 mg · wk 18 · n 2747 | NCT01986881 Phase 3, secondary |
| glimepiride | -0.9 | 0.3 (Glimepiride) | — | 25 mg QD · wk 12 · n 104 | NCT01318083 Phase 2/3, secondary |
| IcoSema | -1.9 | -1.6 (Insulin Icodec) | — | wk 52 · n 552 | NCT05352815 Phase 3, secondary |
| insulin degludec | -3.0 | -3.0 (Insulin Icodec) | — | wk 26 · n 290 | NCT04795531 Phase 3, secondary |
| insulin detemir | -2.1 | -0.4 (Lira 1.8) | — | wk 26 · n 160 | NCT00856986 Phase 3, secondary |
| insulin glargine | -3.6 | -2.1 (Liraglutide) | — | wk 24 · n 468 | NCT01117350 Phase 4, secondary |
| insulin icodec | -3.0 | -3.0 (Insulin Degludec) | — | wk 26 · n 284 | NCT04795531 Phase 3, secondary |
| Insulin Lispro | -2.0 | -1.5 (Insulin Lispro + Insulin Glargine) | — | wk 26 · n 345 | NCT02229227 Phase 3, secondary |
| Linagliptin | -0.4 | 0.3 | −0.6 | 5 mg · wk 24 · n 614 | NCT00954447 Phase 3, secondary |
| Liraglutide (Victoza) | -1.1 | 0.8 | −1.9 | 1.8 mg · wk 26 · n 66 | NCT01541215 Phase 3, secondary |
| lixisenatide | -0.3 | 0.0 | −0.3 | wk 24 · n 171 | NCT01798706 Phase 3, secondary |
| metformin | 0.3 | 0.0 | +0.2 | wk 12 · n 46 | NCT02099838 Phase 4, secondary |
| Omarigliptin | -0.3 | -0.1 | −0.2 | 25 mg · wk 24 · n 102 | NCT01814748 Phase 3, secondary |
| orforglipron | -2.0 | -1.1 | −0.9 | 3/6/12/21 mg QD · wk 12 · n 7 | NCT04426474 Phase 1, secondary |
| SAR341402 | -0.5 | -0.2 (NovoLog/NovoRapid) | — | wk 26 · n 301 | NCT03211858 Phase 3, secondary |
| Saxagliptin | -0.6 | -0.3 | −0.2 | 5 mg · wk 24 · n 300 | NCT00757588 Phase 3, secondary |
| Semaglutide (Ozempic) | -2.1 | -0.9 | −1.2 | 1.0 mg · wk 104 · n 822 | NCT01720446 Phase 3, secondary |
| Sitagliptin | -0.7 | 0.3 | −0.9 | 100 mg · wk 24 · n 234 | NCT00087516 Phase 3, secondary |
| Sotagliflozin (Inpefa) | -1.3 | -0.6 | −0.8 | 400 mg · wk 26 · n 259 | NCT02926950 Phase 3, secondary |
| Teneligliptin | -0.8 | 0.2 | −0.9 | 20 mg · wk 24 · n 122 | NCT02924064 Phase 3, secondary |
| Trelagliptin | -0.9 | -0.0 | −0.9 | 25 mg · wk 12 · n 55 | NCT02512068 Phase 3, secondary |
| Vildagliptin | -1.2 | -0.0 | −1.2 | wk 12 · n 78 | NCT02002221 Phase 4, secondary |
Drugs checked with no result here: 40 not posted, 19 trial running, 22 not reported.
3-point MACE (% with event)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Alogliptin | 11.3% | 11.8% | −0.5 | n 2701 | NCT00968708 Phase 3, primary |
| dulaglutide | 12% | 13.4% | −1.4 | n 4949 | NCT01394952 Phase 3, primary |
| Empagliflozin | 10.4% | 12.1% | −1.7 | 10 mg · n 2345 | NCT01131676 Phase 3, primary |
| Linagliptin | 20.7% | 21.2% (Glimepiride) | — | wk 432 · n 3023 | NCT01243424 Phase 3, primary |
| Liraglutide (Victoza) | 13% | 14.9% | −1.9 | wk 260 · n 4668 | NCT01179048 Phase 3, primary |
| Saxagliptin | 7.4% | 7.4% | ±0 | n 8280 | NCT01107886 Phase 4, primary |
| Semaglutide (Ozempic) | 6.6% | 8.9% | −2.3 | n 1648 | NCT01720446 Phase 3, primary |
| Tirzepatide (Mounjaro) | 12.2% | 13.1% (Dulaglutide) | — | MTD · wk 259 · n 6586 | NCT04255433 Phase 3, primary |
Drugs checked with no result here: 56 not posted, 27 not reported, 20 trial running.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 111 approved or late-stage drugs with a featured trial in Type 2 Diabetes were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.